• Explore /
  • Poster
  • / I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.

I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.

Abstract Poster

Authors

Joe Chang

Joe Y. Chang

The University of Texas MD Anderson Cancer Center, Houston, TX

Joe Y. Chang , Steven H. Lin , Luyang Yao , Saumil Gandhi , Zhongxing X. Liao , Stephen G. Chun , Melenda Jeter , James William Welsh , Percy Lee , Mara Antonoff , Lei Feng , J. Jack Lee , John Heymach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03110978

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9035)

DOI

10.1200/JCO.2020.38.15_suppl.9035

Abstract #

9035

Poster Bd #

228

Abstract Disclosures

Similar Posters

First Author: Joe Y. Chang

First Author: Gustavo Schvartsman

First Author: Aasems Jacob

First Author: Kim Leitzel